Compare L & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | L | RVMD |
|---|---|---|
| Founded | 1969 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0B | 19.2B |
| IPO Year | 1998 | N/A |
| Metric | L | RVMD |
|---|---|---|
| Price | $109.48 | $96.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $120.47 |
| AVG Volume (30 Days) | 523.5K | ★ 1.6M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.23% | N/A |
| EPS Growth | ★ 24.34 | N/A |
| EPS | ★ 7.97 | N/A |
| Revenue | ★ $18,454,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $411.49 |
| P/E Ratio | $13.93 | ★ N/A |
| Revenue Growth | ★ 5.39 | N/A |
| 52 Week Low | $82.49 | $34.00 |
| 52 Week High | $114.90 | $124.49 |
| Indicator | L | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 56.54 | 48.24 |
| Support Level | $107.84 | $93.39 |
| Resistance Level | $112.32 | $101.00 |
| Average True Range (ATR) | 2.10 | 3.12 |
| MACD | 0.46 | 0.21 |
| Stochastic Oscillator | 70.49 | 51.05 |
Loews Corp is a holding company along with its subsidiary engaged in commercial property and casualty insurance, transportation and storage of natural gas and natural gas liquids, operation of a chain of hotels, and also in the manufacture of rigid plastic packaging solutions. It has four reportable segments comprised of three individual consolidated operating subsidiaries, CNA Financial Corporation, Boardwalk Pipeline Partners, LP and Loews Hotels Holding Corporation; and the Corporate segment.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.